GRACE :: Lung Cancer

Moffitt Cancer Center

Can addition of a “heat shock protein inhibitor” to standard chemo improve outcomes in advanced NSCLC?

Share

Drs. Mary Pinder, Nate Pennell, and Jack West discuss the results presented at ASCO 2013 of the GALAXY-1 trial of the HSP90 inhibitor ganetespib combined with Taxotere (docetaxel) as second line therapy for advanced NSCLC.

Discuss this post in the GRACE Discussion Forums


Is there a best Avastin-containing regimen for first line and maintenance therapy in advanced NSCLC?

Share

Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the POINTBREAK trial of maintenance therapy with the ECOG 4599 regimen vs. carboplatin/Alimta (pemetrexed)/Avastin (bevacizumab) followed by Alimta/Avastin maint.

Discuss this post in the GRACE Discussion Forums


Do you need Avastin in first line and maintenance therapy in advanced NSCLC?

Share

Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the PRONOUNCE trial of the ECOG 4599 trial regimen compared with carboplatin/Alimta (pemetrexed) followed by maintenance Alimta. 

Discuss this post in the GRACE Discussion Forums


Can we predict which patients will benefit from Tarceva based on a blood test?

Share

Drs. Mary Pinder, Nate Pennell, and Jack West review results from the PROSE trial presented at ASCO 2013, testing the predictive value of the Veristrat test of serum proteomics to assess the potential value of erlotinib (Tarceva) in advanced NSCLC.

Discuss this post in the GRACE Discussion Forums


Is there a role for molecular markers predicting the best chemotherapy to use in lung cancer?

Share

Drs. Nate Pennell, Mary Pinder, and Jack West discuss trials presented at ASCO 2013 testing the potential value of molecular marker testing to select optimal chemo for advanced non-small cell lung cancer (NSCLC).

Discuss this post in the GRACE Discussion Forums


Is it possible to test for biomarkers in lung cancer on a national scale?

Share

This is the first video in our series from a program filmed directly from ASCO 2013. Drs. Nate Pennell, Mary Pinder, and Jack West discuss the Biomarkers France trial of testing on a national scale for clinically relevant biomarkers in advanced non-small cell lung cancer (NSCLC).

 

>> Discuss this GRACEcast Video in the GRACE Discussion Forums

 


Is it possible to test for biomarkers in lung cancer on a national scale?

Share

Drs. Nate Pennell, Mary Pinder, and Jack West discuss the Biomarkers France trial of testing on a national scale for clinically relevant biomarkers in advanced non-small cell lung cancer (NSCLC).

Discuss this post in the GRACE Discussion Forums


Ask Us, Q&A
Lung/Thoracic Cancer Expert Content

Archives

Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog

Other Resources